Cardiome Updates Guidance

    TSX: COM

    VANCOUVER, Nov. 26 /CNW/ - Cardiome Pharma Corp. (NASDAQ:   CRME /
TSX: COM) today announced updated guidance for expected interim results from
its Phase 2b clinical trial for vernakalant (oral). Cardiome had originally
intended to complete and disclose the interim analysis in the fourth quarter
of 2007. The Company has decided to complete and disclose the interim analysis
in March 2008, with the final study results to be presented in mid-2008.
    "While we remain blinded to the efficacy data from the ongoing study, we
do know that a significant proportion of our enrollment has occurred in the
past two months, meaning that those patients have not yet progressed deeply
into the 90-day program," stated Doug Janzen, President and Chief Business
Officer of Cardiome. "By delaying one quarter we expect to add roughly
20 percent more patients into the interim analysis than originally planned,
and as a result more data will be available on patients with longer-term
exposure. More than 400 patients have been randomized in the study, and
enrollment is expected to be complete in early 2008."
    "In the context of current business development activities and corporate
discussions, we have decided that generating a very robust interim analysis
with a large number of patients is in the best interests of shareholders,"
stated Bob Rieder, Chairman and Chief Executive Officer of Cardiome. "While we
are all looking forward to seeing data from this study as soon as possible, we
believe that the larger dataset that we can gather under this revised timeline
will be highly beneficial in our efforts to drive shareholder value in the
first half of 2008. In accordance with our disclosure practice, we will
release the results of the interim analysis in a timely manner upon receipt of
un-blinded results."
    The Phase 2b clinical trial of vernakalant (oral) for the prevention of
recurrence of atrial fibrillation was initiated in the first quarter of 2007.
The double-blind, placebo-controlled, randomized, dose-ranging study is
designed to measure the safety and efficacy of vernakalant (oral) over 90 days
of oral dosing in patients at risk of recurrent atrial fibrillation, and is
expected to enroll approximately 670 patients of which 500 to 600 are expected
to enter the maintenance phase and be measured for efficacy.

    About Cardiome Pharma Corp.

    Cardiome Pharma Corp. is a product-focused cardiovascular drug
development company with two late-stage clinical drug programs focused on
atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for
GED-aPC, an engineered analog of recombinant human activated Protein C, and a
pre-clinical program directed at improving cardiovascular function.
    Vernakalant (iv) is the intravenous formulation of an investigational
drug being evaluated for the acute conversion of atrial fibrillation (AF).
Positive top-line results from two pivotal Phase 3 trials for vernakalant
(iv), called ACT 1 and ACT 3, were released in December 2004 and September
2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a
New Drug Application for vernakalant (iv) in December 2006. Positive top-line
results from an additional Phase 3 study evaluating patients with
post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An
open-label safety study evaluating recent-onset AF patients, called ACT 4, has
    Vernakalant (oral) is being investigated as a chronic-use oral drug for
the maintenance of normal heart rhythm following termination of AF. Cardiome
announced positive results from a Phase 2a pilot study for vernakalant (oral)
in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.
    In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC
for all indications. Cardiome intends to initially develop GED-aPC in
cardiogenic shock, a life-threatening form of acute circulatory failure due to
cardiac dysfunction, which is a leading cause of death for patients
hospitalized following a heart attack.
    Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ
National Market (CRME).

    Forward-Looking Statement Disclaimer

    Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including without
limitation statements containing the words "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar
expressions. Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements or information. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with the completion of clinical trials and
obtaining regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that:
we may not be able to successfully develop and obtain regulatory approval for
vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation
or any other current or future products in our targeted indications; our
future operating results are uncertain and likely to fluctuate; we may not be
able to raise additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we may not be
able to establish marketing and sales capabilities and the costs of launching
our products may be greater than anticipated; we rely on third parties for the
continued supply and manufacture of vernakalant (iv) and vernakalant (oral)
and we have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange Commission
available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to
place undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.

For further information:

For further information: Peter K. Hofman, Senior Director, Investor
Relations, (604) 676-6993 or Toll Free: 1-800-330-9928, Email:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890